Kilian Eyerich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7226009/publications.pdf

Version: 2024-02-01

106 papers	6,477 citations	38 h-index	77 g-index
121	121	121	8052 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. Journal of Clinical Investigation, 2009, 119, 3573-85.	3.9	840
2	Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 336-349.	1.5	465
3	Increasing Comorbidities Suggest that Atopic DermatitisÂlsÂaÂSystemic Disorder. Journal of Investigative Dermatology, 2017, 137, 18-25.	0.3	283
4	ILâ€17 and ILâ€22 in immunity: Driving protection and pathology. European Journal of Immunology, 2017, 47, 607-614.	1.6	264
5	Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 974-982.	2.7	257
6	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157, 1047.	2.0	236
7	IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune response. Journal of Allergy and Clinical Immunology, 2009, 123, 59-66.e4.	1.5	220
8	IL-17 and IL-22: siblings, not twins. Trends in Immunology, 2010, 31, 354-361.	2.9	206
9	Cutaneous Barriers and Skin Immunity: Differentiating A Connected Network. Trends in Immunology, 2018, 39, 315-327.	2.9	204
10	Patients with Chronic Mucocutaneous Candidiasis Exhibit Reduced Production of Th17-Associated Cytokines IL-17 and IL-22. Journal of Investigative Dermatology, 2008, 128, 2640-2645.	0.3	203
11	Mutual Antagonism of T Cells Causing Psoriasis and Atopic Eczema. New England Journal of Medicine, 2011, 365, 231-238.	13.9	196
12	Precision assessment of label-free psoriasis biomarkers with ultra-broadband optoacoustic mesoscopy. Nature Biomedical Engineering, 2017, 1 , .	11.6	187
13	Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Science Translational Medicine, 2014, 6, 244ra90.	5.8	170
14	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775.	1.4	127
15	ILâ€22 and TNFâ€Î± represent a key cytokine combination for epidermal integrity during infection with <i>Candida albicans</i> . European Journal of Immunology, 2011, 41, 1894-1901.	1.6	122
16	Immune response patterns in nonâ€communicable inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 692-703.	1.3	110
17	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 321-333.	0.9	108
18	Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. Journal of Investigative Dermatology, 2018, 138, 1555-1563.	0.3	92

#	Article	IF	CITATIONS
19	New biological treatments for asthma and skin allergies. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 546-560.	2.7	70
20	The Multi-Modal Immune Pathogenesis of Atopic Eczema. Trends in Immunology, 2015, 36, 788-801.	2.9	68
21	Sodium chloride is an ionic checkpoint for human T $<$ sub $>$ H $<$ /sub $>$ 2 cells and shapes the atopic skin microenvironment. Science Translational Medicine, 2019, 11, .	5.8	66
22	Sebum lipids influence macrophage polarization and activation. British Journal of Dermatology, 2017, 177, 1671-1682.	1.4	63
23	Human and computational models of atopic dermatitis: AÂreview and perspectives by an expert panel of the International Eczema Council. Journal of Allergy and Clinical Immunology, 2019, 143, 36-45.	1.5	58
24	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	2.7	58
25	Generalized pustular psoriasis – a model disease for specific targeted immunotherapy, systematic review. Experimental Dermatology, 2018, 27, 1067-1077.	1.4	56
26	Relations between epidermal barrier dysregulation and Staphylococcus species–dominated microbiome dysbiosis in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2018, 142, 1643-1647.e12.	1,5	56
27	A novel molecular disease classifier for psoriasis and eczema. Experimental Dermatology, 2016, 25, 767-774.	1.4	54
28	Type I Immune Response Induces Keratinocyte Necroptosis and Is Associated with Interface Dermatitis. Journal of Investigative Dermatology, 2018, 138, 1785-1794.	0.3	52
29	Sebocytes contribute to skin inflammation by promoting the differentiation of T helper 17 cells. British Journal of Dermatology, 2018, 178, 722-730.	1.4	51
30	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	1.3	50
31	Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 2021, 10, 2094.	1.8	50
32	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	2.7	47
33	COVIDâ€19 and immunological regulations – from basic and translational aspects to clinical implications. JDDG - Journal of the German Society of Dermatology, 2020, 18, 795-807.	0.4	45
34	Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in human subjects. Journal of Allergy and Clinical Immunology, 2018, 141, 1320-1333.e11.	1,5	44
35	Human exposure to airborne pollen and relationships with symptoms and immune responses: Indoors versus outdoors, circadian patterns and meteorological effects in alpine and urban environments. Science of the Total Environment, 2019, 653, 190-199.	3.9	44
36	Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin. Journal of Allergy and Clinical Immunology, 2020, 146, 8-16.	1.5	44

#	Article	IF	CITATIONS
37	Addiction: an underestimated problem in psoriasis health care. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1308-1315.	1.3	43
38	Motion correction in optoacoustic mesoscopy. Scientific Reports, 2017, 7, 10386.	1.6	43
39	Efficacy and safety of dupilumab for moderateâ€toâ€severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	2.7	41
40	Th22 cells in allergic disease. Allergo Journal International, 2015, 24, 1-7.	0.9	40
41	Pollen Grains Induce a Rapid and Biphasic Eczematous Immune Response in Atopic Eczema Patients. International Archives of Allergy and Immunology, 2008, 145, 213-223.	0.9	39
42	Assessing nailfold microvascular structure with ultra-wideband raster-scan optoacoustic mesoscopy. Photoacoustics, 2018, 10, 31-37.	4.4	39
43	Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)â€syndrome: a new entity within the spectrum of autoinflammatory syndromes?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 141-143.	1.3	37
44	Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Archives of Dermatological Research, 2019, 311, 421-424.	1.1	36
45	Nonâ€invasive imaging in dermatology and the unique potential of rasterâ€scan optoacoustic mesoscopy. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1051-1061.	1.3	35
46	Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab. JAMA Dermatology, 2016, 152, 482.	2.0	32
47	Psoriasis Pathogenesis: Keratinocytes Are Back inÂtheÂSpotlight. Journal of Investigative Dermatology, 2019, 139, 995-996.	0.3	31
48	The Impact and Consequences of SARS-CoV-2 Pandemic on a Single University Dermatology Outpatient Clinic in Germany. International Journal of Environmental Research and Public Health, 2020, 17, 6182.	1.2	31
49	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open, 2021, 11, e049822.	0.8	31
50	Allergic Contact Dermatitis in Psoriasis Patients: Typical, Delayed, and Non-Interacting. PLoS ONE, 2014, 9, e101814.	1.1	30
51	STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC. Journal of Investigative Dermatology, 2018, 138, 711-714.	0.3	29
52	The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 5-12.	3.3	28
53	ILâ€17C amplifies epithelial inflammation in human psoriasis and atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 800-809.	1.3	26
54	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	1.3	25

#	Article	IF	CITATIONS
55	Guselkumab is superior to fumaric acid esters in patients with moderateâ€toâ€severe plaque psoriasis who are naive to systemic treatment: results from a randomized, activeâ€comparatorâ€controlled phase IIIb trial (POLARIS). British Journal of Dermatology, 2020, 183, 265-275.	1.4	24
56	EAACI Biologicals Guidelines—dupilumab for children and adults with moderateâ€toâ€severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 988-1009.	2.7	24
57	Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey. American Journal of Clinical Dermatology, 2022, 23, 65-71.	3.3	24
58	Skin symptoms as diagnostic clue for autoinflammatory diseases. Anais Brasileiros De Dermatologia, 2017, 92, 72-80.	0.5	23
59	Cytokines of the ILâ€17 family in psoriasis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 675-681.	0.4	22
60	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.4	22
61	So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis. Journal of Internal Medicine, 2021, 290, 27-39.	2.7	21
62	Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2429-2435.	1.3	20
63	NOS2 and CCL27: clinical implications for psoriasis and eczema diagnosis and management. Expert Review of Clinical Immunology, 2015, 11, 167-169.	1.3	20
64	EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17Âyears old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	2.7	19
65	Allergy and sensitization to Hymenoptera venoms in unreferred adults with a high risk of sting exposure. World Allergy Organization Journal, 2019, 12, 100039.	1.6	17
66	Treatment of Pityriasis Rubra Pilaris With Guselkumab. JAMA Dermatology, 2019, 155, 1424.	2.0	17
67	Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1158-1172.	2.7	16
68	Tofacitinib in Hypertrophic Lichen Planus. Acta Dermato-Venereologica, 2020, 100, adv00220.	0.6	16
69	Requirements and expectations of highâ€quality biomarkers for atopic dermatitis and psoriasis in 2021—a twoâ€round Delphi survey among international experts. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1467-1476.	1.3	14
70	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 494-506.	1.4	14
71	Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwiâ€allergic donor. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1136-1139.	1.3	13
72	Generalized pustular psoriasis—Dawn of a new era in targeted immunotherapy. Experimental Dermatology, 2020, 29, 1088-1096.	1.4	13

#	Article	IF	CITATIONS
73	Optical features of human skin revealed by optoacoustic mesoscopy in the visible and short-wave infrared regions. Optics Letters, 2019, 44, 4119.	1.7	13
74	Patientâ€reported outcomes with risankizumab versus fumaric acid esters in systemic therapyâ€naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1686-1691.	1.3	12
75	Ekzem oder Psoriasis? Eine spezielle Herausforderung in der Berufsdermatologie. Dermatologie in Beruf Und Umwelt, 2018, 66, 113-119.	0.5	12
76	Enabling precision monitoring of psoriasis treatment by optoacoustic mesoscopy. Science Translational Medicine, 2022, 14, eabm8059.	5.8	12
77	Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3003-3006.	2.7	11
78	Lipomatous Metaplasia after Severe and Chronic Cutaneous Inflammation. Dermatology, 2008, 217, 52-55.	0.9	10
79	Is the humoral immunity dispensable for the pathogenesis of psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 115-122.	1.3	10
80	Optoacoustic mesoscopy shows potential to increase accuracy of allergy patch testing. Contact Dermatitis, 2020, 83, 206-214.	0.8	10
81	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study. Biomedicines, 2021, 9, 1698.	1.4	10
82	Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naìve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology, 2022, 186, 30-39.	1.4	9
83	Keratinocytes Regulate the Threshold of Inflammation by Inhibiting T Cell Effector Functions. Cells, 2021, 10, 1606.	1.8	8
84	Urban vs rural – Prevalence of self-reported allergies in various occupational and regional settings. World Allergy Organization Journal, 2022, 15, 100625.	1.6	8
85	Continued treatment with secukinumab is associated with high retention or regain of response. British Journal of Dermatology, 2019, 182, 67-75.	1.4	7
86	Biologics in the treatment of skin and rheumatologic diseases. Journal of Allergy and Clinical Immunology, 2020, 145, 1138-1141.	1.5	7
87	T-Cell‒Mediated Autoimmunity: Mechanisms and Future Directions. Journal of Investigative Dermatology, 2022, 142, 804-810.	0.3	7
88	Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. JDDG - Journal of the German Society of Dermatology, 2022, 20, 287-295.	0.4	7
89	Always Online? Internet Addiction and Social Impairment in Psoriasis across Germany. Journal of Clinical Medicine, 2020, 9, 1818.	1.0	6
90	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. Dermatology and Therapy, 2022, 12, 81-95.	1.4	6

#	Article	IF	CITATIONS
91	Successful treatment of recalcitrant dyshidrotic eczema with dupilumab in a child. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1165-1167.	0.4	5
92	The power and potential of BIOMAP to elucidate hostâ€microbiome interplay in skin inflammatory diseases. Experimental Dermatology, 2021, 30, 1517-1531.	1.4	5
93	Addictions in Patients with Atopic Dermatitis: A Crossâ€sectional Pilot Study in Germany. Journal of the European Academy of Dermatology and Venereology, 2021, , .	1.3	4
94	Ixekizumab for acrodermatitis continua. JDDG - Journal of the German Society of Dermatology, 2018, 16, 907-910.	0.4	3
95	Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 3-18.	1.3	3
96	Transferability of suggested molecular classifiers for psoriasis and eczema to the Chinese population. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e189-e192.	1.3	3
97	<scp>DMARD</scp> s in psoriasis: a critical appraisal. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 388-388.	1.3	1
98	Recurrent swelling of the ear. JDDG - Journal of the German Society of Dermatology, 2018, 16, 96-98.	0.4	1
99	Atopisches Ekzem: die Basis nicht vergessen!. JDDG - Journal of the German Society of Dermatology, 2018, 16, 963-964.	0.4	1
100	Counteracting lipids orchestrate type 2 immunity. Journal of Allergy and Clinical Immunology, 2019, 144, 1175-1176.	1.5	1
101	Assessing genotypes to predict therapeutic outcome in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, $11-12$.	1.3	1
102	CD23 Levels on B Cells Determine Long-Term Therapeutic Response in Patients with Atopic Eczema Treated with Selective IgE Immune Apheresis. Journal of Investigative Dermatology, 2021, 141, 681-685.e6.	0.3	1
103	IFN-1s: Sentinels Shaping Distinct Immune Responses in Skin. Journal of Investigative Dermatology, 2021,	0.3	1
104	Muscle hypertrophy and onychodystrophy. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1278-1281.	0.4	0
105	Multiple pustular lesions in a patient with ulcerative colitis – successfully treated with TNFâ€alphaâ€inhibitor. JDDG - Journal of the German Society of Dermatology, 2021, 19, 782-784.	0.4	0
106	Molekulardiagnostik in der Dermatologie: Eine Onlineâ€Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in Deutschland. JDDG - Journal of the German Society of Dermatology, 2022, 20, 287-296.	0.4	0